title: Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects.
abstract: OBJECTIVE
  We compared differences associated with use of travoprost and latanoprost on both progression of perimetric loss over time and associated costs among black patients.
  
  
  METHODS
  Patients with primary open-angle glaucome or ocular hypertension were randomly assigned to one of four arms in a 12-month, double-masked study: travoprost (0.004% or 0.0015%), latanoprost (0.005%), or timolol (0.5%). Forty-nine patients received 0.004% travoprost, 43 received latanoprost, and 40 received timolol. We applied algorithms found in published studies that link intraocular pressure (IOP) control to visual field progression and calculated the likelihood of visual field deterioration based on IOP data. This was used to estimate differences in medical care costs.
  
  
  RESULTS
  The average IOP was lower for patients receiving travoprost than for patients receiving latanoprost or timolol (17.3 versus 18.7 versus 20.5 mm Hg respectively, P < .05). Travoprost-treated patients had a smaller predicted change in visual field defect score (VFDS) than latanoprost-treated patients and timolol-treated patients, and significantly fewer were expected to demonstrate visual field progression. Medical care costs would be higher for latanoprost-treated and timolol-treated patients.
  
  
  CONCLUSIONS
  Recent studies have provided algorithms linking IOP control to changes in visual fields. We found that treatment with travoprost was associated with less visual field progression and potential cost savings.
authors.affiliation: Alcon Research, Ltd, Fort Worth, Texas, USA.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Halpern
authors.forename: David W
authors.initials: DW
authors.lastname: Covert
authors.forename: Alan L
authors.initials: AL
authors.lastname: Robin
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use*; D044383:Black People; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D018450:Disease Progression; D004311:Double-Blind Method; D016527:Drug Costs; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000191:economics / Q000208:ethnology* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000191:economics / Q000208:ethnology / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000191:economics / Q000627:therapeutic use; D013999:Timolol / Q000191:economics / Q000627:therapeutic use; D000069557:Travoprost; D014481:United States; D014786:Vision Disorders / Q000503:physiopathology*; D014794:Visual Fields / Q000187:drug effects*; D001741:Black or African American
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D013999:Timolol; D000069557:Travoprost